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Abstract 
Since the early 1990s, the concept of primary “inherited” arrhythmia syndromes 
or ion channelopathies has evolved rapidly as a result of revolutionary progresses made 
in molecular genetics.  Alterations in genes coding for membrane proteins such as ion 
channels or their associated proteins responsible for the generation of cardiac action 
potentials (AP) have been shown to cause specific malfunctions which eventually lead 
to cardiac arrhythmias. These arrhythmic disorders include congenital long QT 
syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, 
short QT syndrome, progressive cardiac conduction disease, etc.  Among these, long 
QT and Brugada syndromes are the most extensively studied, and drugs cause a 
phenocopy of these two diseases. To date, more than 10 different genes have been 
reported to be responsible for each syndrome. More recently, it was recognized that 
long QT syndrome can be latent, even in the presence of an unequivocally pathogenic 
mutation (silent mutation carrier). Co-existence of other pathological conditions in these 
silent mutation carriers may trigger a malignant form of ventricular arrhythmia, the so 
called torsade de pointes (TdP) that is most commonly brought about by drugs. In 
analogy to the drug-induced long QT syndrome, Brugada type 1 ECG can also be 
induced or unmasked by a wide variety of drugs and pathological conditions; so 
physicians may encounter patients with a latent form of Brugada syndrome. Of 
particular note, Brugada syndrome is frequently associated with atrial fibrillation whose 
therapeutic agents such as Vaughan Williams class IC drugs can unmask the dormant 
and asymptomatic Brugada syndrome. This review describes two types of drug-induced 
arrhythmias: the long QT and Brugada syndromes.  
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Abbreviations: 
AP, Action potential; BrS, Brugada syndrome; ERS, Early repolarization syndrome; 
ECG, Electrocardiogram; LQTS, Long QT syndrome; RVOT, Right ventricular outflow 
tract; SDR, Spatial dispersion of repolarization; SNP, Single nucleotide polymorphism; 
SCD, Sudden cardiac death; SIDS, Sudden infant death syndrome; TdP, Torsade de 
pointes; VF, Ventricular fibrillation; VT, Ventricular tachycardia 
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1. Introduction 
For hundreds of years since the introduction of pharmacological therapeutics, 
drug-induced arrhythmias which may lead to fatal outcomes have been recognized to 
occur. One of the first recognized forms of drug-induced fatal arrhythmias was the so-
called ‘quinidine syncope’ (Selzer and Wray, 1964). Later, Vaughan Williams class IA 
drugs like quinidine or disopyramide were found to block the rapid component of 
outward (repolarizing) potassium current (designated as IKr), thereby prolonging the 
action potential (AP) duration and leading to fatal ventricular arrhythmias (Figure 1C) 
(Dessertenne, 1966). Ironically, quinidine is now a widely accepted treatment and the 
most frequently used drug for Brugada syndrome (BrS) as well as early repolarization 
syndrome (ERS) owing to its inhibitory effect on transient outward currents (Ito) 
(Belhassen et al., 2015; Sacher et al., 2014). Similar to the drug-induced long QT 
syndrome (LQTS), numerous agents are reported to cause BrS (or Brugada type 1 ECG 
pattern) through blockage of the depolarizing (inward) sodium or calcium channels.  
Therefore, intrinsically, these two forms of drug-induced fatal arrhythmias are distinct in 
terms of arrhythmogenic circumstances created by the culprit drug. The former results 
from a blockade in outward currents, thereby enabling early afterdepolarizations; and 
the latter results from a blockade in inward currents and cardiac conduction delay (Priori 
et al., 2013).  In this review, we will describe drug-induced arrhythmias and their 
underlying mechanisms in the setting of ion channel diseases.   
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2. Current Concept of Long QT Syndromes 
Since the clinical advent of electrocardiography (ECG) in the early 20th century, 
an abnormally prolonged QT interval was recognized to be associated with familial 
sudden death, and this syndrome was designated as congenital LQTS (Jervell and 
Lange-Nielsen, 1957; Romano et al., 1963; Ward, 1964). However, the novel concept of 
ion channel diseases has emerged and rapidly evolved only in the last two decades, 
and our understanding was deepened thanks to the detailed studies that were first done 
on LQTS (Curran et al., 1995; Priori et al., 2013; Sanguinetti et al., 1995; Wang et al., 
1996; Wang et al., 1995a; Wang et al., 1995b). The LQTS, indeed, played the role of 
Rosetta Stone in the conceptualization of ion channel disorders as predicted by Dr. D. 
Zipes (Zipes, 1991). 
In his 1991 review, Dr. Zipes predicted that LQTS could be the key disease that 
can serve to elucidate the pathologic mechanisms underlying sympathetic ventricular 
tachycardia (VT) as Wolff-Parkinson-White syndrome did serve to advance our 
understanding of reentry mechanisms. He hypothesized that the cause of the disease 
was an intrinsic abnormality of repolarization that lied within the heart itself: abnormal 
channel proteins reducing or blocking an outward (repolarizing) potassium currents or 
increasing inward (depolarizing) calcium or sodium currents. Figure 1 presents this 
concept schematically (Horie and Itoh, 2007). 
Congenital LQTS is now recognized as a heterogeneous disease entity 
characterized by prolonged ventricular repolarization associated with episodes of 
syncope and/or life-threatening cardiac arrhythmias, specifically TdP. In 1991, the same 
year of Dr. Zipes’ review paper (Zipes, 1991), Keating and co-workers, using linkage 
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analyses, demonstrated that a DNA marker near the Harvey ras-1 locus (H-ras-1) on 
chromosome 11 was associated with LQTS (later classified as type 1: LQT1) (Keating 
et al., 1991). Four years later, in 1995, the same group found hERG (human ether-à-go-
go-related gene), now referred to as KCNH2, to be responsible for LQT2 and SCN5A 
for LQT3 (Curran et al., 1995; Sanguinetti et al., 1995; Wang et al., 1995b).  The 
SCN5A gene encodes the pore-forming α-subunit of the cardiac voltage-gated sodium 
channel (NaV1.5), the channel responsible for the generation and subsequent 
propagation of cardiac AP through the heart. In the following 20 years, a multitude of 
variants in the genes encoding cardiac ion channels or their associated proteins have 
been shown to result in the malfunction of these proteins and thereby cause different 
types of inherited arrhythmias (Priori et al., 2013).  On the basis of genetic testing, the 
prevalence of congenital LQTS is reported to be approximately 1/2,000 (Schwartz et al., 
2009). Syncope is generally the first and most common manifestation of the disease, 
while sudden cardiac death (SCD) is rare (1–3%) (Zareba et al., 1998).  Of the patients 
who eventually become symptomatic, 50% experience their first cardiac event by the 
age of 12, and 90% by the age of 40 (Moss et al., 1991).  LQTS is also known to 
present itself as sudden infant death syndrome (SIDS) (Schwartz et al., 1998).  A 
mutation in an LQTS-causing gene is found in approximately 10% of infants with SIDS 
(Arnestad et al., 2007). 
 At the very early stage of channelopathy research, the malfunction of ion 
channels was thought to be intrinsic (or congenital), but it was gradually recognized that 
extrinsic factors, especially drugs, can modulate cardiac ion channel function, and even 
result in their dysfunction. It is now widely accepted that there is a substantial number of 
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silent variant (or mutation) carriers (Itoh et al., 2016; Itoh et al., 2009; Priori et al., 1999). 
Even if the victims of drug-induced TdP show no other signs suggestive of congenital 
LQTS, there are still a substantial number of latent LQTS individuals amongst them 
carrying mildly dysfunctional variants of LQTS-related genes which would still be 
classified as congenital LQTS. These latent congenital LQTS forms should be strictly 
differentiated from “pure” drug-induced LQTS. With specific genotype knowledge in 
hand, a less restrictive “drugs to avoid” list can be created to avoid further impairment of 
the particular gene product that is dysfunctional, similar to the gene-specific therapies 
being investigated in congenital LQTS (Mazzanti et al., 2016). Therefore, genetic tests 
are of paramount clinical importance not only to the victims of drug-induced fatal 
arrhythmias, but also to their family members if they are suspected to be silent variant 
carriers.    
In this connection, we very recently screened for the five major LQTS genes 
among 188 acquired LQTS probands, including drug-induced ones from Japan, France 
and Italy. In 53 subjects (28%), 47 disease-causing rare variants were identified with the 
majority of these being in KCNH2, which is at variance with previous reports of 
congenital LQTS (Itoh et al., 2016).  In this study, we also proposed a novel scoring 
system based on QT duration corrected for the heart rate, age and symptoms that can 
help physicians to identify individuals that are more likely to carry the LQTS variants. 
Again, it is of extreme importance to perform cascade screening in family members of 
drug-induced LQTS patients in order to identify silent mutation carriers who are at 
potential risk of drug-induced sudden cardiac death.  
 Only less than 1% of the genome is not identical between two unrelated 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 10 
individuals and this tiny variability allows them to be distinguished by means of genetic 
analyses. When genetic variations at a given region are seen in more than 1% of the 
general population, this variant is defined as “polymorphism”; while when seen in less 
than 0.5% of the general population, the variant would be defined as “rare” 
polymorphism or mutation. Among genetic variations, single nucleotide polymorphisms 
(SNPs) are quite common and thought to specify the characteristics of each individual. 
When these SNPs are non-synonymous and cause substitution of amino acids, 
functions of the encoded proteins may be altered.  
 Up to date, several SNPs that are functionally normal in the absence of drugs 
have been found to be associated with drug-induced arrhythmias (Itoh et al., 2016; Itoh 
et al., 2009; Kaab et al., 2012; Nishio et al., 2009; Paulussen et al., 2004; Priori et al., 
1999; Sesti et al., 2000). The fact that the Kv11.1 encoded by KCNH2 is a major target 
of drugs, as will be described, may partially explain the unusually high frequency of 
KCNH2 variants in acquired or drug-induced LQTS. For example, Sesti et al. (Sesti et 
al., 2000) identified a common polymorphism in KCNE2, which encodes MinK-related 
peptide 1 (MiRP1), the α -subunit of the Kv11.1 channel. The authors screened for 
variations in KCNE2 in 98 patients with drug-induced LQTS and found the T8A 
polymorphism, which is also found in approximately 1.6% of the general population, in a 
patient with sulfamethoxazole-associated LQTS. In functional analysis, this SNP did not 
cause K+ current reduction at baseline, but it significantly increased the sensitivity to 
inhibition K+ currents by sulfamethoxazole.   
Similarly, the SNP D85N in KCNE1 which encodes the α-subunit of cardiac 
voltage-gated potassium channels was reported to be more prevalent in drug-induced 
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LQTS patients than in controls (Paulussen et al., 2004). This was also found to be the 
case in our cohort of LQTS probands where one homozygous and 23 heterozygous 
carriers were found (allele frequency 3.9%), which was significantly higher compared to 
the controls (0.81%) (Nishio et al., 2009). Recently, Kääb et al. conducted a study in 
drug-induced LQTS patients and they identified 1,386 SNPs tagging common haplotype 
blocks and 38 SNPs in 18 ion channel-associated genes. Again, KCNE1-D85N was 
found to predict drug-induced LQTS with an odds ratio of 9.0, with the variant allele 
being present in 8.6% of cases, 2.9% of drug-exposed control subjects, and 1.8% of 
population control subjects (Kaab et al., 2012).  
More recently, in silico simulation programs were developed using mathematical 
models integrating the action of drugs on individual ion channels based on data 
obtained from ex-vivo studies (Mirams et al., 2011). Although this approach has been 
suggested to improve the cardiac safety assessment of newly-developed drugs, a one-
size-fits-all approach without taking individual genetic differences into account would fall 
short of predicting drug safety in a given patient. Incorporating an individual’s genetic 
data (such as SNPs that are shown to be associated with drug-induced changes in ion 
channel function) would mold these simulation programs into more robust and reliable 
risk prediction tools (Kubo et al., 2017). 
 
3. Drug-induced Long QT Syndrome 
While acquired forms of LQTS are also characterized by QT prolongation and TdP, 
these are provoked by the presence of extrinsic triggers such as QT-prolonging drugs, 
hypokalemia or hypomagnesemia, and bradycardia. The QT-prolonging drugs, which 
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are the most common culprit in acquired LQTS, include many of those in common use 
such as antihistamines, antibiotics, antidepressants, prokinetics. Therefore, drug-
induced LQTS is of substantial concern to clinicians as they portend an unacceptable 
risk of arrhythmic sudden death in certain individuals. This concern have led to the 
withdrawal of many newly developing, otherwise useful agents following the observance 
of a small number of cases with QT prolongation and arrhythmias in phase 2 and 3 
stages of drug development. 
 In 1995, KCNH2 was first reported to be a causative gene for LQTS type 2 
(LQT2) (Curran et al., 1995; Sanguinetti et al., 1995), and Kv11.1, the protein encoded 
by KCNH2, was later found to be a target of numerous agents that cause drug-induced 
LQTS (Mitcheson et al., 2005; Mitcheson et al., 2000; Smith et al., 2016). The 
hydrophobic central cavity of the Kv11.1 channels allows a large number of structurally-
unrelated drugs to bind and render them inactive by plugging the ion conducting pore. 
Moreover, some of the culprit drugs interfere with trafficking of channel proteins from the 
endoplasmic reticulum to the cell membrane, thereby decreasing the channel 
membrane density (Cubeddu, 2009; 2016).   
In addition to these inhibitory actions asserted directly by the QT-prolonging 
drugs, genetic variations in genes coding for the proteins metabolizing these drugs can 
also result in drug-induced QT prolongation by altering their serum levels (McBride et al., 
2009). Moreover, as a result of drug-drug interactions, co-administered drugs can also 
alter the quantity or function of the proteins that are activating the QT-prolonging drug or 
clearing it from the body, resulting in an increase in the effective concentration of the 
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culprit drug, eventually causing prolongation of the QT interval and fatal arrhythmias 
(Dresser et al., 2000; Makita et al., 2002; Simard et al., 2001). 
The list for QT-prolonging drugs is very long: antiarrhythmics (specifically 
Vaughan Williams class IA and III agents) (Goineau et al., 2012), prokinetics (cisapride) 
(Drici and Barhanin, 2000; Itoh et al., 2009; Makita et al., 2002; Rampe et al., 1997; 
Toga et al., 2007), antifungals (ketoconazole) (Cubeddu, 2016; Dumaine et al., 1998), 
antihistamines (terfenadine and astemizole) (Rampe et al., 1993; Salata et al., 1995; 
Wang et al., 2003; Woosley, 1996; Woosley et al., 1993), antiparkinsonian drugs 
(amantadine and budipine) (Scholz et al., 2003; Vernier et al., 1969), antibiotics 
(erythromycin) (Dumaine et al., 1998; Goineau et al., 2012; Itoh et al., 2009), 
antihyperlipidemics (probucol) (Guo et al., 2011; Guo et al., 2007; Hayashi et al., 
2004), antipsychotics (haloperidol (Suessbrich et al., 1997) and phenothiazines 
(Drici et al., 1998; Katchman et al., 2006)).  Here, we do not touch on every culprit 
drug because a number of papers on drug-induced QT prolongation have been 
published. For a more comprehensive and updated list of QT-prolonging drugs, the 
reader is encouraged to access the frequently updated website at 
https://www.crediblemeds.org. 
 
4. Current Concept of Brugada Syndrome 
Brugada Syndrome (BrS) has been recognized as an important cause of SCD at 
a young age. In Southeast Asia, it is the most common cause of natural death in the 
young healthy population (Vatta et al., 2002). BrS is estimated to be responsible for 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 14 
about 20% of sudden deaths in victims with structurally normal hearts and the mean 
age for SCD is around 40 years of age (Antzelevitch et al., 2005b). 
BrS is recognized by the characteristic coved-type ST elevations (denoted as type 1) 
in right precordial leads in the absence of structural heart disease. Figure 2 depicts 
typical ECG features induced by pilsicainide tolerance test. According to the J-Wave 
Syndromes Expert Consensus Report published in 2016 (Antzelevitch et al., 2016), BrS 
is diagnosed by the following criteria:  
1. In patients with spontaneous type 1 ST-segment elevation of 2 mm or more in at 
least one lead among leads V1-V3, positioned in the 2nd, 3rd or 4th intercostal space; 
or, 
2. In patients with drug-induced type 1 ST-segment elevation of 2 mm or more in at 
least one lead among leads V1-V3, positioned in the 2nd, 3rd or 4th intercostal space 
and at least one of the following: (i) unexplained SCD or documented VF/ polymorphic 
VT, (ii) nocturnal agonal respirations, (iii) syncope of probable arrhythmic cause, (iv) first 
or second degree relative with definite BrS.  
In this consensus document, the team of experts also proposed a weighted scoring 
system that could enable clinicians to rule in probable BrS when above conditions are 
not fully met. For example, ECG abnormalities can wax and wane over short periods of 
time, sometimes resulting in diagnosis only after SCD occurs. With the scoring system, 
one could still rule in probable BrS with a combination of other ominous findings. 
Therefore, transientness of the ECG findings underscores the importance of genetic 
and/or drug provocation testing in cases suspicious for aborted SCD, documented 
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VT/VF or inducible VT/VF in cases suspicious for BrS, unexplained syncope, seizures, 
nocturnal agonal respirations, family history of unexplained sudden death before 45 
years of age or spontaneous type 1 ECG pattern. Likewise, a comprehensive family 
screening should be performed after diagnosis of an index case is made. A negative 
cardiac test, however, should not be relied on to exclude BrS, rather the comprehensive 
clinical history should be taken into account while making diagnostic and therapeutic 
decisions (Ackerman et al., 2011). 
In 1992, BrS was presented as a genetic disorder showing familial aggregation 
that was associated with a characteristic ECG pattern and sudden cardiac death 
secondary to polymorphic VT or VF (Brugada and Brugada, 1992). Only 6 years later, 
within a time frame that can be considered quite short for finding the molecular culprit 
for a newly described syndrome, the cardiac sodium channel encoding gene, SCN5A, 
was found to be associated with BrS (Chen et al., 1998). To date, more than 300 exonic 
mutations were identified in SCN5A resulting in BrS. Moreover, promoter region 
polymorphisms, intronic mutations, epigenetic and posttranslational modifications 
modulating the functional expression of SCN5A were also found to be implicated in the 
syndrome (Beltran-Alvarez et al., 2011; Bezzina et al., 2006; Fernández-Falgueras et 
al., 2016; Hong et al., 2005; Park et al., 2012). However, BrS is genetically very 
heterogeneous. While most common gene disorder resulting in BrS involve the gene 
SCN5A (accounting for 20-30% of the cases), there are more than 20 other genes 
found to be associated with BrS (Juang and Horie, 2016; Kapplinger et al., 2010; 
Watanabe and Minamino, 2016). 
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As new genes are being added to the list of culprit genes, new mutations in 
already known genes are also being discovered with newly diagnosed and reported 
cases (Turker et al., 2016). Apart from mutations, there are also common variants in 
cardiac ion channel genes that are not likely to cause harm on their own, but can 
predispose the carriers to drug-induced arrhythmias such as the polymorphism in 
MiRP1 gene mentioned above in relation to drug-induced TdP (Abbott et al., 1999). A 
common variant allele of SCN5A (Y1102), which is present in 13-19% of African 
Americans, was found to strongly predispose harboring individuals to drug-induced 
arrhythmias (Splawski et al., 2002). Similarly, the common SCN5A promoter haplotype 
seen in 22% of the Asian population was found to account for 48% of variability in 
response to Na channel blocking agents, causing individuals carrying this haplotype to 
be more prone to developing diagnostic BrS ECG and arrhythmia susceptibility (Bezzina 
et al., 2006). 
The vast majority of these polymorphisms predisposing the carriers to full BrS 
phenotype are yet to be discovered, but with genome-wide association studies, more 
are being found (Bezzina et al., 2013). In the future, results from these studies will shed 
light on drug-induced arrhythmias that occur in people who have been tested to be 
negative for the already known variants. Unfortunately, all of the genetic mechanisms 
identified thus far can only explain up to 30-35% of the BrS cases (Sarquella-Brugada et 
al., 2016). Moreover, even though 20 years ago BrS was described in structurally 
normal hearts, with today’s technology, structural abnormalities are being identified in 
patients diagnosed with BrS making the assessment of genetic contribution more 
complicated (Catalano et al., 2009; Rudic et al., 2016; van Hoorn et al., 2012). 
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Mechanisms behind creation of macroscopic arrhythmias by cellular current 
changes remain controversial. Mainly two hypotheses, based on repolarization or 
depolarization changes, have been proposed and might be acting alone or in 
conjunction. The first hypothesis proposes amplification of the inherent differences in 
repolarization patterns of the different layers of myocardium which is commonly referred 
to as the spatial dispersion of repolarization (SDR) (Antzelevitch, 2001). Ito is the most 
important current ascribed to SDR. It is present in the epicardial cells and M cells, but 
not in the innermost of the three myocardial layers, the endocardium (Figure 3A) 
(Antzelevitch, 2001). Moreover, in the right ventricle, Ito is of nearly threefold magnitude 
compared to the left ventricle which is behind the arrhythmogenesis of right ventricular 
origin in BrS (Di Diego et al., 1996).  
Transmural voltage difference in phase 1 repolarization caused by 
heterogeneous expression of Ito between endocardium and epicardium explains the 
abnormal J point elevation seen in BrS (Figure 3B) (Antzelevitch, 2001). Ito prominence 
subjects cells to all-or-none repolarization once the nadir of AP phase 1 reaches below 
the activation threshold of L-type calcium channels resulting in loss of AP dome and 
shortening of the AP duration (Figure 3C) (Yan and Antzelevitch, 1999). This is 
contributed by certain pathophysiologic conditions and drug interventions that decrease 
depolarizing currents (ischemia, sodium or calcium channel blockers, potassium 
channel openers etc.) (Antzelevitch, 2005). Heterogeneous loss of the AP dome in the 
epicardium results in epicardial dispersion of repolarization and contributes more to the 
inherent transmural heterogeneity. When the dome of AP is lost in epicardial cells, but 
not in endocardial cells, a transmural voltage gradient between endocardium and 
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epicardium occurs, showing itself as the characteristic ST segment elevations inscribed 
on the ECG (Yan and Antzelevitch, 1999).   
Progression of currents, within the epicardium or transmurally, from areas where 
phase 2 is preserved to those where it is lost, cause short coupled re-excitations named 
phase 2 re-entry which provides the trigger for VT and VF seen in BrS (Figure 3D) 
(Wilde et al., 2002). This hypothesis is also supported by the ECG response of BrS 
patients to autonomic changes; i.e. parasympathetic activation induced increase in Ito 
and/or decrease in ICa attenuate the spike and dome pattern of the AP increasing the 
dispersion of repolarization and accentuating the ST elevation seen on ECG (Litovsky 
and Antzelevitch, 1990; Miyazaki et al., 1996; Mizumaki et al., 2004; Noda et al., 2002). 
Furthermore, Ito blockers quinidine and 4-aminopyridine abolish phase 2 re-entry and 
resultant polymorphic VT that is provoked with pinacidil in canine wedge preparations 
(Yan and Antzelevitch, 1999). The importance of Ito in development of arrhythmias 
through dispersion of repolarization was further demonstrated by comparison of two 
class 1 antiarrhythmic agents, ajmaline and flecainide. In a study by Wolpert et al., while 
ajmaline induced Brugada type ECG in 22 of 22 patients with suspected BrS, flecainide 
induced it in only 15 of the 22 patients. This was attributed to the greater Ito blocking 
properties of flecainide but not of ajmaline. It is thought that with more Ito blockage, 
flecainide better counteracts the loss of inward currents asserted by similar INa blocking 
effects of these drugs, thereby causes less shortening of the AP duration in the RVOT 
and less dispersion of repolarization (Wolpert et al., 2005). Recently, Antzelevitch et al., 
on a canine wedge BrS model created with NS5806-induced increase in Ito and 
verapamil induced decrease in ICa, observed late potentials and fractionated activities 
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on electrograms from epicardium but not from endocardium that is attributed to the 
heterogeneousness of phase 2 of the AP (Szel and Antzelevitch, 2014). This finding fits 
with fractionated electrograms observed in BrS patients (Nademanee et al., 2011). Also, 
in support of the major role played by Ito are the prevalence studies that show an 8-10 
fold more occurrence of BrS in males (Priori et al., 2013). This is thought to be due to 
the presence of a more prominent transient outward current (Ito) in males (Di Diego et 
al., 2002). Supporting this, Matsuo et al. (Matsuo et al., 2003) reported disappearance 
of BrS ECG pattern in two males after castration. In addition to being more prevalent, 
male BrS presents with a more serious initial risk profile and worse outcomes. Males 
show greater VF inducibility in electrophysiologic studies and 4-5 times more SCD than 
women (Benito et al., 2008). In a cohort of 30 children, no male predisposition for BrS 
was found, supporting the effect of androgens, which are absent in children (Probst et 
al., 2007). 
A second hypothesis for development of arrhythmias in BrS proposes slowing of 
depolarization and conduction by fibrosis and decreased INa in RVOT as the primary 
mechanism. Relatively delayed depolarization in RVOT with respect to other sites of RV 
creates regional potential differences that ascribe itself as the ST-segment elevation 
seen on the right precordial leads (Coronel et al., 2005) (Meregalli et al., 2005) (Figure 
4). This hypothesis is also supported by less drug-induced ST segment elevation 
provoked by weaker INa blockers, disopyramide and procainamide, compared to 
stronger ones such as ajmaline (Shimizu et al., 2000). Similarly, class 1B agents have 
no role in provocation because of less INa blocking properties in slow or moderate heart 
rates (Miyazaki et al., 1996; Shimizu et al., 2000). This hypothesis is also supported by 
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Postema et al.’s cardiac mapping study that showed delayed depolarization over the 
RVOT of BrS patients (Postema et al., 2008). Recently, Nadamanee et al. showed that 
BrS patients exhibited fractionated electrograms over the RVOT epicardium and 
ablation of areas with slow conduction eliminated the BrS ECG pattern in 8 of 9 cases 
(Nademanee et al., 2011). Further supporting this hypothesis is the presence of 
differentially conducting myocytes in the RVOT which initially develops as a slow 
conducting tissue and subsequently gains rapid conduction properties during 
development. Heterogeneity of the conduction caused by remnants of the embryonic 
tissue creates regional potential differences, triggering arrhythmias (Boukens et al., 
2009). 
Other mechanisms of BrS phenotype and development of arrhythmias involve 
abnormal neural crest cell migration, dysfunctional gap junction communication and 
connexome abnormalities. A discussion on these can be found in a recent review article 
by Dr. Brugada and colleagues (Sieira et al., 2016).  
 
5. Drug-induced Brugada Syndrome 
In biologically predisposed patients, environmental factors could modulate the 
observed phenotype. These individuals may have latent ion channel dysfunction that 
increases the susceptibility to acquired forms of BrS similar to drug-induced LQTS. 
Autonomic changes, hormonal changes, alcohol, fever, and medications can turn a 
normal ECG to a BrS ECG. Several studies reported that exercise (Kasanuki et al., 
1997; Nademanee et al., 1997), atropine (Kasanuki et al., 1997) and isoproterenol 
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infusion (Kasanuki et al., 1997; Miyazaki et al., 1996) could normalize a BrS ECG, 
whereas muscarinic (Kasanuki et al., 1997; Miyazaki et al., 1996) and selective α-
adrenoceptor stimulation (Miyazaki et al., 1996), through reflex vagal activation, could 
augment the ST elevation. This also explains the propensity of VT/VF episodes during 
night time in BrS. Similarly, while targeting sympathetic activity via left cardiac 
sympathetic denervation is a widely accepted therapy for intractable LQTS (Turker and 
Ai, 2014), it may increase arrhythmias in BrS. In a prospective cohort study of 17 LQTS 
patients who underwent sympathetic denervation, a patient with BrS-LQTS overlap 
syndrome was the only one to continue having arrhythmias after other causes were 
excluded (Olde Nordkamp et al., 2014). Several studies reported successful prevention 
of intractable episodes of VF in BrS using phosphodiesterase inhibitors, milrinone (Szel 
et al., 2013) and cilostazol (Shinohara et al., 2014; Szel et al., 2013; Tsuchiya et al., 
2002). These drugs elevate cyclic AMP levels in the cell and increase L-type calcium 
current (ICa), thereby restoring the epicardial AP dome. 
Recently, a cohort of suspected BrS patients who had a negative response to 
ajmaline challenge were re-challenged after they reached puberty (age 16) and 23% of 
them were found to have converted to a positive response which underscores the 
influence of hormonal and autonomic changes of puberty on BrS phenotype (Conte et 
al., 2014). 
Fever has long been recognized as a risk factor for arrhythmias seen in BrS. 
Some SCN5A mutations cause alteration in sodium channel kinetics only at high 
temperatures (Dumaine et al., 1999; Samani et al., 2009). Other studies have 
suggested that sensibility to fever may not be due to mutations, but due to temperature-
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dependent properties of the wild-type SCN5A or Ito, as well as fever induced facilitation 
of spontaneous activity in RVOT and Purkinje fibers (Keller et al., 2005; Pasquie et al., 
2004).  Although the exact mechanisms of fever-induced arrhythmias remain 
controversial, many reports of fever-provoked BrS phenotype underscore the 
importance of antipyretic management in patients with BrS (Barra et al., 2013; Kum et 
al., 2002; Morita et al., 2002; Porres et al., 2002; Saura et al., 2002). On the other 
extreme, cold exposure can also result in unmasking of the BrS phenotype by 
increasing Ito (Nishida et al., 2004; Noda et al., 2003). 
Ischemia involving the RVOT depresses L-type ICa and activates IKATP, 
unmasking BrS ECG (Kataoka, 2000). It can then be inferred, agents resulting in 
vasospasm and ischemia could increase the chance of arrhythmias in predisposed 
subjects (Chinushi et al., 2001; Noda et al., 2002). This also makes treatment of 
spontaneous vasospasm challenging in BrS as both nitrates and calcium channel 
blockers commonly used to treat coronary vasospasm could also induce the BrS 
phenotype (Antzelevitch et al., 2005b). 
As can be summarized from above discussions, any drug that would decrease INa 
or ICa or increase Ito would be arrhythmogenic in BrS. According to their mechanism of 
action, these drugs can be classified into three major groups: 
5-1. Sodium Channel Blockers 
The amplitude of INa underlies the maximum positive membrane potential 
reached at the end of AP phase 0. If INa is diminished, then AP phase 1 starts at lower 
membrane potential and ends at more negative potentials. The balance of inward and 
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outward currents at the end of phase 1 determines whether or not ICa can overcome the 
outward currents and induce formation of the AP dome. Since endocardium and 
epicardium have different responses to INa blocking agents (Krishnan and Antzelevitch, 
1991), they cause transmural heterogeneity in the formation of the AP dome. Class IA 
and IC antiarrhythmic agents are therefore utilized in unmasking the BrS phenotype. 
Figure 2 shows pilsicainide-induced ECG changes in a patient with drug-induced BrS 
who received the drug for treatment of atrial fibrillation. Generally class IC agents with 
the exception of flecainide have stronger INa blocking effects than IA agents due to a 
faster dissociation of the latter class from the sodium channels. Class IB agents, on the 
other hand, are not as effective because of their small effect on INa at normal heart 
rates.   
Tricyclic antidepressants (amitriptyline (Bolognesi et al., 1997; Rouleau et al., 
2001), desimipramine (Babaliaros and Hurst, 2002), nortriptyline (Bigwood et al., 2005; 
Tada et al., 2001), clomipramine (Goldgran-Toledano et al., 2002), imipramine (Ogata 
and Narahashi, 1989), etc.) and tetracyclic  antidepressants (maprotiline (Bolognesi et 
al., 1997)), via their sodium channel blocking effects, are known to precipitate Brugada 
type ECG by diminishing the net inward current at the end of phase 1 AP. Among 
tricyclic antidepressants, amitriptyline and imipramine are also shown to reduce Ito 
activation. (Casis and Sanchez-Chapula, 1998; Delpon et al., 1992) Moreover, 
amitriptyline also blocks IKr (Jo et al., 2000). Ito and IKr blockage can compensate for the 
decrease in INa and explain why amitriptyline fails to induce BrS phenotype when used 
alone (Minoura et al., 2012).  
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Neuroleptic drug class phenothiazines (chlorpromazine (Ogata and Narahashi, 
1989), trifluoperazine (Klockner and Isenberg, 1987; Rouleau et al., 2001), 
cyamemazine (Crumb et al., 2006; Rouleau et al., 2001), perphenazine (Bolognesi et 
al., 1997)), haloperidol (Ogata and Narahashi, 1989) and loxapine (Rouleau et al., 
2001) can induce BrS type ECG via sodium channel blocking properties.  
SSRIs, particularly fluoxetine, have sodium and calcium channel blocking 
properties in mammalian ventricular myocytes and have been shown to induce BrS type 
ECG (Pacher et al., 2000b; Rouleau et al., 2001). Another SSRI, citalopram, has been 
found to inhibit activation of INa as well (Pacher et al., 2000a). Other SSRIs, fluvoxamine 
(Stirnimann et al., 2010) and paroxetine (Bigwood et al., 2005) are also reported to 
unmask BrS ECG. Antihistaminic agents terfenadine (Di Diego et al., 2002), 
dimenhydrinate (Pastor et al., 2001) and diphenhydramine, (Lopez-Barbeito et al., 
2005) through sodium channel blocking properties, precipitate BrS. It should be noted 
that tricyclic antidepressants, phenothiazines and antihistaminics have anticholinergic 
properties as well and would be expected to neutralize the Brugada phenotype; 
however, it is thought that the phenotype shows itself because of more predominant 
blockage of sodium channels than of muscarinic receptors with these drugs.  
Antihistaminic drug, terfenadine, which has both INa and ICa blocking properties 
was shown to be more effective in provoking VT than INa blockers alone in canine 
models of ventricular wedge preparations (Fish and Antzelevitch, 2004). Among sodium 
channel blocking agents those with potent Ito blocking effects (flecainide and 
disopyramide) (Virag et al., 1998; Wolpert et al., 2005) are less likely or even not likely 
(quinidine) (Alings et al., 2001) to induce arrhythmogenesis. Lithium (Darbar et al., 
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2005), cocaine (Bebarta and Summers, 2007; Littmann et al., 2000; Ortega-Carnicer et 
al., 2001), cannabis (Romero-Puche et al., 2012), alcohol (Habuchi et al., 1995; 
Rouleau et al., 2001) and anesthetic agents (propofol (Vernooy et al., 2006a), 
bupivacaine (Vernooy et al., 2006b), ketamine (Hara et al., 1998)) also unmask BrS 
phenotype by decreasing INa. Even though methadone is better known for its 
association with drug-induced long QT Syndrome, it has also been reported to induce 
BrS ECG (Junttila et al., 2008). Another synthetic opioid tramadol which blocks neuronal 
sodium channels is also reported to unmask BrS type ECG (Cole et al., 2012). Many 
antiepileptic medications assert their affect via blockage of the neuronal sodium 
channels. Some of these have also been shown to alter cardiac sodium channel kinetics 
(Xu et al., 1991), while some are yet to be shown to do so. A word of caution on the 
subject of sodium channel blockers and BrS should be made in the treatment of patients 
presenting with seizures.  
Patients who develop a syncopal episode and found in a “post-ictal state” could 
have had an arrhythmic episode and found in a state of confusion due to cerebral 
hypoperfusion which could be mistaken for post-ictal status. In these patients well-
intended therapeutic maneuvers with sodium channel blocking antiepileptic medications 
(phenytoin, carbamazepine, primidone, lamotrigine, and topiramate etc.) could induce 
BrS and have deleterious consequences. Therefore, diagnosis of seizure disorder 
should only be made after careful exclusion of the possibility of BrS. 
5-2. Potassium Channel Openers 
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The balance of inward and outward currents at the end of AP phase 1 
determines whether or not repolarization will occur in an all-or-none fashion; therefore, 
any increase in outward currents (IKATP, Ito, and IKr) can cause loss of the AP dome and 
result in a vulnerable window in voltage gradients between areas where these currents 
are differentially expressed. IKATP activators, pinacidil (Di Diego et al., 2002) and 
nicorandil (Robert et al., 1999), have been shown to cause loss of the AP dome in areas 
where Ito is prominent with resultant phase-2 reentry in experimental models. Glucose 
and insulin could unmask the BrS phenotype by decreasing serum potassium 
concentrations and accentuating Ito (Nishizaki et al., 2003). Nogami et al. were able to 
provoke Brugada phenotype with insulin and glucose in 7 out of 7 men who had aborted 
SCD (Nogami et al., 2003). Diuretics and distal renal tubular acidosis can act in a 
similar manner by decreasing serum potassium levels (Mok et al., 2008; Nimmannit et 
al., 1991).  
5-3. Calcium Channel Blockers 
ICa is the main current to form the AP dome. If it is diminished and cannot 
overcome the outward balance of currents at the end of phase 1 AP, the dome 
disappears. It has been shown that Ito which is the main current responsible for 
formation of phase 1 is heterogeneously expressed in between different layers of the 
myocardium (Litovsky and Antzelevitch, 1988), therefore a strong ICa acts as the rescuer 
of the AP dome where Ito is increased. The basis of provocation of BrS phenotype with 
calcium channel blockers, in part, is due to failing to reach the potential threshold 
needed to rescue the AP dome in areas where Ito is strong (RVOT). Calcium channel 
blockers (Chinushi et al., 2006; Fish and Antzelevitch, 2008) and β-blockers (Grace and 
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Camm, 2000; Kasanuki et al., 1997) unmask BrS by decreasing L-type calcium 
currents. Litovsky et al. showed that acetylcholine, by inhibition of ICa, can result in loss 
of the AP dome and trigger arrhythmias (Litovsky and Antzelevitch, 1990). Nitrates, 
similarly, have L-type Ca channel blocking properties and could induce BrS phenotype 
(Matsuo et al., 1998). Of the INa blockers listed above, trifluoperazine (Klockner and 
Isenberg, 1987), cyamemazine (Crumb et al., 2006), fluoxetine (Pacher et al., 2000b), 
terfenadine (Fish and Antzelevitch, 2004), ketamine (Hara et al., 1998), alcohol 
(Habuchi et al., 1995) etc. also block ICa increasing the effects of these drugs in 
uncovering the BrS phenotype. 
5-4. Treatment and Prevention of Drug-induced BrS 
Drug-induced BrS phenotype is not benign. In a recent series of 47 patients with 
drug-induced BrS ECG, 51% developed malignant arrhythmias (Junttila et al., 2008). 
Interestingly, however, not all the cases share similar prognosis. For example, when 
tricyclic antidepressants are the culprit for Brugada type ECG, malignant arrhythmias 
are far less common (Behr and Camm, 2008). In a recent review of 74 cases of drug-
induced BrS, it was found that 31% of patients developed arrhythmias with a mortality 
rate of 14%. The only characteristics that differentiated patients who developed 
arrhythmias from those who did not were younger age and non-oral route of 
administration for the culprit drugs. Both in those with and without arrhythmias, duration 
of exposure to the drug before the BrS ECG developed was weeks to years, making 
ECG screening at the time of drug initiation impractical (Konigstein et al., 2016). 
Immediate withdrawal of the offending drug is effective in most BrS cases. If additional 
treatment is needed, agents that restore the inward and outward current balance can be 
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used. Isoproterenol has been shown to decrease the ST elevation inscribed by the 
dispersion of repolarization and suppress electrical storm in BrS patients (Miyazaki et 
al., 1996; Watanabe et al., 2006) (Ohgo et al., 2007). Cilostazol (Shinohara et al., 2014; 
Szel et al., 2013; Tsuchiya et al., 2002), bepridil (Ohgo et al., 2007), and milrinone (Szel 
et al., 2013) have also been shown to suppress VF in BrS patients. According to the J-
Wave Syndromes Expert Consensus Report published in 2016, a drug-induced type 1 
ST segment elevation in one of the right precordial leads is sufficient for the diagnosis of 
BrS when combined with various other clinical features (Antzelevitch et al., 2016). 
Therefore, in those with induced BrS, the offending agent or condition should be 
immediately withdrawn or treated and these individuals should be counseled on: (a) 
avoidance of drugs that may induce or aggravate ST-segment elevation in right 
precordial leads (for a dynamic list visit: http://www.brugadadrugs.org/) (Postema et al., 
2009), (b) avoidance of excessive alcohol intake, and (c) immediate treatment of fever 
with antipyretic drugs.  
Postema et al. initiated a dynamic website in 2009 as a repository of potentially 
arrhythmogenic drugs (Postema et al., 2009). This website is frequently updated as new 
drugs are added to or deleted from the implicated drugs list. In addition to being a 
professional resource of information for caregivers, it also serves as a resource for 
patients themselves in case they want to check the drugs they should avoid. The drugs 
on the website are listed in four categories: 1) drugs to be avoided by BrS patients; 2) 
drugs preferably avoided by BrS patients; 3) potential antiarrhythmic drugs in BrS 
patients; 4) diagnostic drugs in BrS. The recommendations follow the familiar 
AHA/ACC/ESC guidelines format and should be of help to physicians caring for 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 29 
individuals with suspected BrS and to patients diagnosed with BrS (Postema et al., 
2009). A tabular form of the drugs discussed in this article can be viewed in Table 1. 
 
6. Future Perspectives  
Drug-induced fatal arrhythmias are not uncommon. Substantial genetic 
background has been shown to underlie the predisposition to drug-induced arrhythmic 
events especially in the absence of structural heart disease. Not only medical 
professionals, but also patients themselves should know the potential culprit drugs that 
trigger LQTS or BrS phenocopy, and websites are very useful for the promotion of this 
type of tailored medicine: https://www.crediblemeds.org and 
http://www.brugadadrugs.org.   
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Table  1 
Sodium Channel Blockers 
Class 1A antiarrhythmics Ajmaline (Brugada et al., 2000; Wolpert et al., 2005), 
procainamide (Brugada et al., 2000), disopyramide (Shimizu 
et al., 2000), cibenzoline (Tada et al., 2000)  
Class 1C antiarrhythmics Pilsicainide (Fujiki et al., 1999; Turker et al., 2016), 
flecainide (Brugada et al., 2000; Fujiki et al., 1999; Krishnan 
and Josephson, 1998; Wolpert et al., 2005), propafenone 
(Matana et al., 2000)  
Antidepressants 
 
Tricyclics (amitriptyline (Bolognesi et al., 1997; Rouleau et 
al., 2001), nortriptyline (Bigwood et al., 2005; Tada et al., 
2001), desipramine (Babaliaros and Hurst, 2002), 
clomipramine (Goldgran-Toledano et al., 2002)), tetracyclics 
(maprotiline (Bolognesi et al., 1997)), SSRIs (fluoxetine 
(Rouleau et al., 2001), paroxetine (Bigwood et al., 2005), 
fluvoxamine (Stirnimann et al., 2010)) 
Neuroleptics 
 
Phenothiazines (chlorpromazine) (Ogata and Narahashi, 
1989), trifluoperazine (Rouleau et al., 2001), cyomemazine 
(Rouleau et al., 2001), perphenazine (Bolognesi et al., 
1997)), haloperidol (Ogata and Narahashi, 1989), lithium 
(Darbar et al., 2005), loxapine (Rouleau et al., 2001) 
Antiepileptics Lamotrigine (Strimel et al., 2010), oxcarbazepine (El-Menyar 
et al., 2011), phenytoin (Swe et al., 2016)  
Anesthetics Propofol (Vernooy et al., 2006a), bupivacaine (Vernooy et 
al., 2006b), ketamine (Hara et al., 1998) 
Analgesics Methadone (Junttila et al., 2008), tramadol (Cole et al., 
2012) 
Antihistaminics Terfenadine (Di Diego et al., 2002; Fish and Antzelevitch, 
2004), dimenhydrinate (Pastor et al., 2001), 
diphenhydramine (Lopez-Barbeito et al., 2005) 
Recreational drugs  Cocaine (Bebarta and Summers, 2007; Littmann et al., 
2000; Ortega-Carnicer et al., 2001), cannabis (Romero-
Puche et al., 2012), alcohol (Rouleau et al., 2001) 
Calcium Channel Blockers 
Verapamil (Chinushi et al., 2006; Fish and Antzelevitch, 2008), diltiazem (Itoh et al., 
1999), nifedipine (Antzelevitch et al., 2005a) 
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Autonomic Regulators  
Acetylcholine (Miyazaki et al., 1996), edrophonium (Kasanuki et al., 1997; Miyazaki et 
al., 1996), neostigmine (Miyazaki et al., 1996), alpha agonists (Miyazaki et al., 1996) 
Beta Blockers 
Propranolol (Aouate et al., 2005; Kasanuki et al., 1997; Tada et al., 2000) 
Potassium Channel Openers 
Pinacidil (Di Diego et al., 2002), nicorandil (Robert et al., 1999) 
Potentially Therapeutic Drugs 
Isoproterenol (Miyazaki et al., 1996; Ohgo et al., 2007; Watanabe et al., 2006), 
cilostazol (Shinohara et al., 2014; Szel et al., 2013; Tsuchiya et al., 2002), bepridil 
(Ohgo et al., 2007), milrinone (Szel et al., 2013) 
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Figure 1. Action potential and QT interval: A) Schematic presentation of ion currents 
contributing to the phases of action potential (AP) in the ventricle. B) AP duration is 
determined by the balance of inward Na+ and Ca2+ currents (blue and yellow arrows) 
and outward K+ current (red arrow) (left panel). An increase in the inward currents or a 
decrease in the outward currents prolongs the AP duration (middle panel) causing long 
QT syndrome (right panel). Abbreviations: I
Na
: sodium current; I
to
: transient outward 
potassium current; I
Ca,L
: L-type calcium current; I
Kr
: rapid component of delayed rectifier 
potassium current; I
Ks
: slow component of delayed rectifier potassium current ; GOF: 
gain of function; LOF: loss of function. Reproduced from Circ J. 71, Suppl A:A50-53 
(Horie and Itoh, 2007) with permission. C) ECG tracing showing the typical onset of 
drug-induced TdP (courtesy of Dr S. Matsuoka, Yamanasi University). 
 
 
 
Figure 2. Pilsicainide-induced Brugada pattern ECG changes: Left panels show 
baseline precordial leads and the right panels show the same after intravenous injection 
of pilsicainide (0.8 mg/kg). Reproduced from PLoS ONE 11(8):e0161872 (Turker et al., 
2016) with permission. 
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Figure 3. Dispersion of repolarization and phase 2 reentry hypothesis in 
Brugada Syndrome: A) Ito is the main current responsible for the phase 1 of the AP 
and is absent in endocardial cells. B) Transmural voltage difference in phase 1 
repolarization caused by heterogeneous expression of Ito between endocardium and 
epicardium explains the abnormal J point elevation seen in J wave syndromes. C) Ito 
prominence and/or decrease in inward sodium or calcium currents in BrS subject cells 
to all-or-none repolarization once the nadir of AP phase 1 reaches below the activation 
threshold of L-type calcium channels thereby resulting in loss of the AP dome and 
shortening of the AP duration. D) Progression of currents, within the epicardium or 
transmurally, from areas where phase 2 is preserved to those where it is lost cause 
short coupled re-excitations named phase 2 re-entry which provides the trigger for VT 
and VF seen in BrS. Modified from J. Cardiovasc. Electrophysiol. 12, 268-272 
(Antzelevitch, 2001) with permission from John Wiley and Sons. 
 
Figure 4. Depolarization (conduction delay) hypothesis in Brugada Syndrome: A 
and B) RVOT action potential is delayed with respect to the rest of the RV.  C) The 
current travels from the more positive RV to the still undepolarized RVOT (a) and loops 
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back towards the RV (b and c). D) The action potential traveling from the RV to RVOT 
and then back to the RV creates the positive and negative inscriptions of the ST 
segment seen in lead V2. E and F) In the next phase of the cardiac cycle, the potential 
gradients between RVOT and RV are reversed due to AP delay in the RVOT and this 
time, the current travels from the RVOT to the RV, resulting in the negative T wave seen 
in Figure 4F. Modified from Cardiovasc Res. 67, 367-378 (Meregalli et. al., 2005) with 
permission. 
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